Compare DraftKings Inc (DKNG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Incyte Corporation — how do they compare? DraftKings Inc trades at $25.31 (market cap $12.51B), while Incyte Corporation trades at $112.62 (market cap $22.95B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals.
| DKNG | INCY | |
|---|---|---|
Market Cap | $12.51B | $22.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $118.52 |
52-Week Low | $20.72 | $67.38 |
Enterprise Value | $13.43B | $18.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $26.45, showing minimal daily movement. The stock exhibits a bullish technical trend with strong moving average signals, supported by a positive cash flow turnaround to $274.40 million in 2025. Revenue growth has been robust, rising from $2.2 billion in 2022 to $6.05 billion in 2025, with the company achieving its first net profit of $3.71 million. Recent expansion into Alberta and the launch of prediction markets highlight ongoing growth initiatives.
The outlook is positive, driven by analyst consensus with a $34.18 price target and 73% buy ratings. Key catalysts include upcoming sports events and product launches, but risks involve high valuation multiples and regulatory scrutiny. Profitability remains nascent, requiring sustained execution to justify current premiums.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
